SCHEMBL4708502

SCHEMBL4708502

CC(=O)c1c(-c2cccc(F)c2)nn(C(C)C)c(=O)c1Nc1cccc(C#N)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNK3 O14649 2/20 0.41
▸ PDE4B Q07343 2/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ PIK3CD O00329 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ HCK P08631 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ PIK3CG P48736 1/20 0.39
▸ EPHB4 P54760 1/20 0.39
▸ PRKDC P78527 1/20 0.39
▸ PI4KB Q9UBF8 1/20 0.39
▸ CSNK1D P48730 2/20 0.39
▸ CSNK1E P49674 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4708005 0.91 ALDH1A1 (0.48) PDE4BPDE4APDE4CPDE4DPIK3CD
SCHEMBL4708887 0.87 PDE4B (0.39) PDE4BCSNK1DCSNK1EBUB1TP53
SCHEMBL4707163 0.87 PDE4B (0.48) PDE4BKDRMTORPOLBBUB1
SCHEMBL4706044 0.86 PDE4B (0.55) KCNK3PDE4BPDE4APDE4CPDE4D
SCHEMBL4706663 0.85 CSNK1E (0.41) PDE4BPIK3CDABL1EGFRHCK
SCHEMBL4706129 0.85 PDE4B (0.44) KCNK3PDE4BPDE4APDE4CPDE4D
SCHEMBL3033451 0.84 CSNK1E (0.45) PDE4BCSNK1DCSNK1EPOLBADORA2A
SCHEMBL4707884 0.83 PDE4B (0.45) PDE4BPIK3CDABL1EGFRHCK
SCHEMBL4706564 0.81 RAB9A (0.39) PDE4BPIK3CDABL1EGFRHCK
SCHEMBL4706113 0.80 PDE4B (0.38) PDE4BPIK3CDABL1EGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 — — US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 — — US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B KCNK3 800/4885PDE4B 3/4885PDE4A 1/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B KCNK3 800/4885PDE4B 3/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback